article thumbnail

Social Media Strategies in Pharma for the Second Half of 2025

Pharma Marketing Network

In 2025, the landscape of healthcare marketing is evolving faster than ever—and nowhere is this more evident than on social media. In 2025, pharma brands are shifting toward engagement-first models that prioritize dialogue over monologue. Moreover, 2025 has seen a surge in partnerships with health influencers and patient advocates.

article thumbnail

Two “Unresolvable” Prescribing/Dispensing Red Flags Unfurled

FDA Law Blog: Biosimilars

We received a response to our post on the prescribing red flags indicating the likelihood of certain prescriptions filled by Walgreens pharmacies were invalid because they lacked a legitimate medical purpose or were not issued in the usual course of professional practice. By Larry K.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHC Comments on Response to the Medicare Program; Request for Information on Medicare Advantage Data

Putting Patients First Blog

Prior authorization and association with delayed or discontinued prescription fills. NHC comments on draft CY 2025 Part D redesign program instructions. Retrieved from [link] Comments-RE-Draft-CY-2025-Part-D-Redesign-Program-Instructions.pdf 15 National Health Council. and Keating, N. Journal of Clinical Oncology, 42(8).

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

12 Mark Kyle and Natalie Keating, “Prior Authorization and Association with Delayed or Discontinued Prescription Fills,” Journal of Clinical Oncology 42, no. Issue Brief: Improving Prescription Drug Price and Cost Transparency. Accessed January 2, 2025. ” Accessed January 9, 2025. 42 Maria T.

article thumbnail

ASBM Statement on President Trump’s Executive Order Supporting Patients Who Depend on Small-Molecule Medicines

Safe Biologics

April 21, 2025 The Alliance for Safe Biologic Medicines (ASBM) commends President Donald J. Small-molecule drugs account for over 90% of all prescriptions filled in the United States. Trump for his leadership in issuing an executive orde r to address the harmful pill penalty contained within the Inflation Reduction Act (IRA).

article thumbnail

January 2025 Newsletter

Safe Biologics

Small molecule drugs make up over 90% of prescriptions filled in the U.S. PBM Reform: Could 2025 Finally See a Long-Awaited Overhaul? As PBMs face increasing scrutiny from lawmakers, regulators, and the public, 2025 presents another chance to address their controversial practices. Read the FTC Report here.